January 24, 2018 / 1:48 PM / in 10 minutes BRIEF-Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/Mabthera Reuters Staff 
Jan 24 (Reuters) - Pfizer Inc: 
* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN®/MABTHERA® 
* PFIZER INC - PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN(®)/MABTHERA(®) 
* PFIZER INC - RESULTS FROM COMPARATIVE REFLECTIONS B3281006 STUDY DEMONSTRATE EQUIVALENCE IN PATIENTS WITH INDOLENT FOLLICULAR LYMPHOMA 
* PFIZER INC - REFLECTIONS B3281006, A COMPARATIVE SAFETY AND EFFICACY STUDY OF PF-05280586 VERSUS MABTHERA(®) (RITUXIMAB-EU), MET ITS PRIMARY ENDPOINT 
* PFIZER - TRIAL DEMONSTRATED EQUIVALENCE IN OVERALL RESPONSE RATE FOR FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Source text for Eikon: Further company coverage: